Molina Healthcare (MOH)
(Delayed Data from NYSE)
$325.43 USD
-4.87 (-1.47%)
Updated Oct 10, 2024 04:00 PM ET
After-Market: $325.43 0.00 (0.00%) 6:30 PM ET
3-Hold of 5 3
A Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$325.43 USD
-4.87 (-1.47%)
Updated Oct 10, 2024 04:00 PM ET
After-Market: $325.43 0.00 (0.00%) 6:30 PM ET
3-Hold of 5 3
A Value F Growth D Momentum D VGM
Zacks News
Mednax (MD) Pursues $1.1B Transactions to Reduce Debt Burden
by Zacks Equity Research
Mednax (MD) issues senior notes, and a new revolving credit facility coupled with a term loan remains in place, which is aimed at reducing MD's debt level and associated interest expenses.
Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aptinyx Inc. (APTX) and Molina (MOH) have performed compared to their sector so far this year.
Humana (HUM) to Support Eligible Medicaid Members in Louisiana
by Zacks Equity Research
Humana (HUM) is picked by the Louisiana Department of Health for a contract win to help serve the Medicaid members in Louisiana.
Ecolab (ECL) Q4 Earnings & Revenues Beat Mark, Margins Down
by Zacks Equity Research
Ecolab's (ECL) robust performance across most of its segments drives its Q4 sales despite business challenges.
Centene (CNC) Boosts Presence in Louisiana With Contract Win
by Zacks Equity Research
Centene's (CNC) latest contract renewal tends to improve health outcomes of Medicaid members of Louisiana.
Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Grow
by Zacks Equity Research
Robust performances by all three operating businesses drove Henry Schein's (HSIC) Q4 revenues.
Omnicell (OMCL) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Robust performance by the Product and Service segments is driving Omnicell's (OMCL) fourth-quarter top line.
Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums
by Zacks Equity Research
Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.
Molina (MOH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 2.13% and 3.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Should SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPMD
Molina (MOH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott's (ABT) Diabetes Arm Booms, Neuromodulation Sales Soft
by Zacks Equity Research
Even though COVID-19 case rates are surging in the United States and other geographies, Abbott is seeing growth in its consumer-facing businesses like nutrition, EPD and diabetes care.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) for Now
by Zacks Equity Research
Investors are optimistic about Tandem Diabetes' (TNDM) t:slim X2 technology and greater use of Control-IQ technology.
Anthem (ANTM) Q4 Earnings Top Estimates
by Zacks Equity Research
Anthem (ANTM) delivered earnings and revenue surprises of 0.59% and 0.91%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Community Health (CYH) Unit Declares Pricing of Senior Notes
by Zacks Equity Research
Community Health's (CYH) wholly-owned arm exhibits monetary discretion by pricing senior notes to procure funds.
Molina Healthcare (MOH) Up 14.4% in 6 Months: Growth Ahead?
by Zacks Equity Research
Molina Healthcare (MOH) is likely to keep growing on the back of increasing membership and higher premium revenues.
Should Vanguard S&P MidCap 400 ETF (IVOO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVOO
Here's Why You Should Retain Cigna (CI) in Your Portfolio
by Zacks Equity Research
Cigna (CI) is well-poised for growth, attributable to solid segmental contributions, the continuous launch of affordable MA plans, a strong partner network and sufficient cash reserves.
Top Analyst Reports for Lowe's, Southern Company & Freeport-McMoRan
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Lowe's Companies, Inc. (LOW), The Southern Company (SO), and Freeport-McMoRan Inc. (FCX).
Here's Why Seasoned Investors are Retaining Mednax (MD)
by Zacks Equity Research
Banking on its strategic measures and a streamlined business, Mednax (MD) holds potential to reap benefits for investors.
Why Holding Anthem (ANTM) in Your Portfolio is a Prudent Move?
by Zacks Equity Research
Riding high on its strategic measures and a rising membership, Anthem (ANTM) holds prospects to reap benefits for investors.
Why Seasoned Investors are Retaining Community Health (CYH)
by Zacks Equity Research
Community Health Systems (CYH) is focused on making strategic acquisitions to boost its business through inorganic growth.
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Centene (CNC) is well poised for growth on the back of improving revenues, continuous expansion plans for the MA business and sufficient cash-generating abilities.
Humana (HUM) Cuts Medicare Enrollment Outlook, Tumbles 19.4%
by Zacks Equity Research
Humana (HUM) expects Group Medicare Advantage membership to remain flat in 2022, with competitive pricing possibly playing a crucial role.
Should iShares Core S&P MidCap ETF (IJH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJH